Last reviewed · How we verify
mRNA transfected dendritic cell
At a glance
| Generic name | mRNA transfected dendritic cell |
|---|---|
| Sponsor | Inge Marie Svane |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer (PHASE2)
- Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer (PHASE1, PHASE2)
- Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma (PHASE1, PHASE2)
- A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) (PHASE2)
- Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients (PHASE1, PHASE2)
- DC Vaccination for Postremission Therapy in AML (PHASE1, PHASE2)
- Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma (PHASE1, PHASE2)
- A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA transfected dendritic cell CI brief — competitive landscape report
- mRNA transfected dendritic cell updates RSS · CI watch RSS
- Inge Marie Svane portfolio CI